|Biological target||HMG-CoA reductase|
Statins (or HMG-CoA reductase inhibitors) are a class of drugs used to lower cholesterol levels by inhibiting the enzyme HMG-CoA reductase, which plays a central role in the production of cholesterol in the liver, which produces about 70 percent of total cholesterol in the body. Increased cholesterol levels have been associated with cardiovascular disease (CVD). Statins have been found to prevent cardiovascular disease in those who are at high risk. The evidence is strong that statins are effective for treating CVD in the early stages of a disease (secondary prevention). However, the evidence is weaker that statins are effective for those with elevated cholesterol levels but without CVD (primary prevention). Side effects of statins include muscle pain, increased risk of diabetes and abnormalities in liver enzyme tests. Additionally they have rare but severe adverse effects, particularly muscle damage. Moreover, some doctors believe that statins are over-prescribed.
As of 2010, a number of statins are on the market: atorvastatin (Lipitor), fluvastatin (Lescol), lovastatin (Mevacor, Altocor), pitavastatin (Livalo), pravastatin (Pravachol), rosuvastatin (Crestor) and simvastatin (Zocor). Several combination preparations of a statin and another agent, such as ezetimibe/simvastatin, are also available. The best-selling statin is atorvastatin which by 2003 became the best-selling pharmaceutical in history. The manufacturer Pfizer reporting sales of US$12.4 billion in 2008.
- 1 Medical uses
- 2 Adverse effects
- 3 Mechanism of action
- 4 Pharmacogenomics
- 5 History
- 6 Available forms
- 7 Research
- 8 References
- 9 External links
Clinical practice guidelines generally recommend people to try "lifestyle modification", including a cholesterol-lowering diet and physical exercise, before statin use; statins or other pharmacologic agents may be recommended for those who do not meet their lipid-lowering goals through diet and lifestyle changes.
Debate exists over whether statins are effective in those with high cholesterol, but no history of heart disease. The best meta-analysis (with individual patient data) did not find a mortality benefit in those at high risk but without prior cardiovascular disease. Other reviews concluded there is a mortality and morbidity benefit, but there were concerns regarding the quality of the evidence. With respect to quality of life, evidence of improvement is limited when statins are used for primary prevention. No studies as of 2010 show improved clinical outcomes in children with high cholesterol though statins decrease cholesterol levels.
Statins are effective in decreasing mortality in people with pre-existing CVD. They are also currently advocated for use in patients at high risk of developing heart disease. On average, statins can lower LDL cholesterol by 1.8 mmol/l (70 mg/dl), which translates into an estimated 60% decrease in the number of cardiac events (heart attack, sudden cardiac death) and a 17% reduced risk of stroke after long-term treatment. They have less effect than the fibrates or niacin in reducing triglycerides and raising HDL-cholesterol ("good cholesterol").
While no direct comparison exists, all statins appear effective regardless of potency or degree of cholesterol reduction. There do appear to be some differences between them, with simvastatin and pravastatin appearing superior in terms of side-effects.
A comparison of atorvastatin, pravastatin and simvastatin, based on their effectiveness against placebos, found, at commonly prescribed doses, no statistically significant differences among agents in reducing cardiovascular morbidity and mortality.
Some[quantify] scientists believe the statins are overused. Their use has expanded into areas where they provide lesser benefit, and lesser evidence of benefit. The lower the risk of cardiovascular events, the lower the ratio is of benefits to costs. The US market for statins nearly tripled when the National Cholesterol Education Program revised its guidelines to recommend statins as primary prevention. Although the panel cited randomized trials to support statin therapy for primary prevention of occlusive cardiovascular disease, a report in Lancet notes, "not one of the studies provides such evidence." 
A group of scientists, The International Network of Cholesterol Skeptics, question the lipid hypothesis and argue that elevated cholesterol has not been adequately shown to cause heart disease. These organizations maintain that statins are not as beneficial or safe as suggested. The beneficial effects of statins are suggested to be due to their working as vitamin D analogues.
|Choosing a statin for people with special considerations|
|Condition||Commonly recommended statins||explanation|
|kidney transplantation recipients taking ciclosporin||Pravastatin or Fluvastatin||Drug interactions are possible, but studies have not shown that these statins increase exposure to ciclosporin.|
|HIV-positive people taking protease inhibitors||Atorvastatin, Pravastatin or Fluvastatin||Significant negative interactions are more likely with other choices|
|persons taking gemfibrozil, a non-statin cholesterol-lowering drug||Atorvastatin||Combining gemfibrozil and a statin increases risk of Rhabdomyolysis and subsequently renal failure|
|persons taking the anticoagulant warfarin||any statin||The statin use may require that the warfarin dose be changed, as some statins increase the effect of warfarin.|
The most common adverse side effects are raised liver enzymes and muscle problems. In randomized clinical trials, reported adverse effects are low; but they are "higher in studies of real world use", and more varied. In randomized trials, statins increased the risk of an adverse effect by 39% compared to placebo (odds ratios 1.4); two-thirds of these were myalgia or raised liver enzymes, with serious adverse effects similar to placebo. However, reliance on clinical trials can be misleading indications of real-world adverse effects – for example, the statin cerivastatin was withdrawn from the market in 2001 due to cases of rhabdomyolysis (muscle breakdown), although rhabdomyolysis was not found in a meta-analysis of published cerivastatin clinical trials. A 2014 systematic review on the side effects of statins found a 0.5% increase in diabetes. Other possible adverse effects include cognitive loss, neuropathy, pancreatic and hepatic dysfunction, and sexual dysfunction.
Some people on statin therapy report myalgias, muscle cramps, or, less frequently, gastrointestinal or other symptoms. Liver enzyme derangements, typically in about 0.5%, are also seen at similar rates with placebo use and repeated enzyme testing, and generally return to normal either without discontinuance over time or after briefly discontinuing the drug. Multiple other side effects occur rarely; typically also at similar rates with only placebo in the large statin safety/efficacy trials. Two randomized clinical trials found cognitive issues, while two did not; recurrence upon reintroduction suggests these are causally related to statins in some individuals. A Danish case-control study published in 2002 suggested a relationship between long-term statin use and increased risk of nerve damage or polyneuropathy, but suggested this side effect is "rare, but it does occur"; other researchers have pointed to studies of the effectiveness of statins in trials involving 50,000 people which have not shown nerve damage as a significant side effect.
Problems with muscles occur in 10-15% of people who take statins. Rare reactions include myositis and myopathy, with the potential for rhabdomyolysis (a significant breakdown of skeletal muscle) leading to possibly acute renal failure. Coenzyme Q10 (ubiquinone) levels are decreased in statin use; CoQ10 supplements are sometimes used to treat statin-associated myopathy, though there was not enough evidence of their effectiveness despite their ability to raise the circulating levels of CoQ10 in blood plasma as of 2007[update]. The gene SLCO1B1 (Solute carrier organic anion transporter family member 1B1) codes for an organic anion-transporting polypeptide that is involved in the regulation of the absorption of statins. A common variation in this gene was found in 2008 to significantly increase the risk of myopathy.
Graham et al. (2004) reviewed records of over 250,000 patients treated from 1998 to 2001 with the statin drugs atorvastatin, cerivastatin, fluvastatin, lovastatin, pravastatin, and simvastatin. The incidence of rhabdomyolyis was 0.44 per 10,000 patients treated with statins other than cerivastatin. However, the risk was over 10-fold greater if cerivastatin was used, or if the standard statins (atorvastatin, fluvastatin, lovastatin, pravastatin, or simvastatin) were combined with fibrate (fenofibrate or gemfibrozil) treatment. Cerivastatin was withdrawn by its manufacturer in 2001.
All commonly used statins show somewhat similar results, but the newer statins, characterized by longer pharmacological half-lives and more cellular specificity, have had a better ratio of efficacy to lower adverse effect rates. Some researchers have suggested hydrophilic statins, such as fluvastatin, rosuvastatin, and pravastatin, are less toxic than lipophilic statins, such as atorvastatin, lovastatin, and simvastatin, but other studies have not found a connection; the risk of myopathy was suggested to be lowest with pravastatin and fluvastatin, probably because they are more hydrophilic and as a result have less muscle penetration. Lovastatin induces the expression of gene atrogin-1, which is believed to be responsible in promoting muscle fiber damage.
They may reduce the risk of esophageal cancer, colorectal cancer, gastric cancer, hepatocellular carcinoma, and possibly prostate cancer. They appear to have no effect on the risk of lung cancer, kidney cancer, breast cancer, pancreatic cancer, or bladder cancer.
Combining any statin with a fibrate or niacin, another category of lipid-lowering drugs, increases the risks for rhabdomyolysis to almost 6.0 per 10,000 person-years. Most physicians have now abandoned routine monitoring of liver enzymes and creatine kinase, although they still consider this prudent in those on high-dose statins or in those on statin/fibrate combinations, and mandatory in the case of muscle cramps or of deterioration in renal function.
Consumption of grapefruit or grapefruit juice inhibits the metabolism of certain statins. Bitter oranges may have a similar effect. Furanocoumarins in grapefruit juice (i.e. bergamottin and dihydroxybergamottin) inhibit the cytochrome P450 enzyme CYP3A4, which is involved in the metabolism of most statins (however, it is a major inhibitor of only lovastatin, simvastatin, and to a lesser degree, atorvastatin) and some other medications (flavonoids (i.e. naringin) were thought to be responsible). This increases the levels of the statin, increasing the risk of dose-related adverse effects (including myopathy/rhabdomyolysis). The absolute prohibition of grapefruit juice consumption for users of some statins is controversial.
The FDA notified healthcare professionals of updates to the prescribing information concerning interactions between protease inhibitors and certain statin drugs. Protease inhibitors and statins taken together may raise the blood levels of statins and increase the risk for muscle injury (myopathy). The most serious form of myopathy, rhabdomyolysis, can damage the kidneys and lead to kidney failure, which can be fatal.
Mechanism of action
Statins act by competitively inhibiting HMG-CoA reductase, the first committed enzyme of the HMG-CoA reductase pathway. Because statins are similar to HMG-CoA on a molecular level, they take the place of HMG-CoA in the enzyme and reduce the rate by which it is able to produce mevalonate, the next molecule in the cascade that eventually produces cholesterol, as well as a number of other compounds. This ultimately reduces cholesterol via several mechanisms. A variety of statins are produced by Penecillium and Aspergillus fungi as secondary metabolites. These natural statins probably function to inhibit HMG-CoA reductase enzymes in bacteria and fungi that compete with the producer.
Inhibiting cholesterol synthesis
By inhibiting HMG-CoA reductase, statins block the pathway for synthesizing cholesterol in the liver. This is significant because most circulating cholesterol comes from internal manufacture rather than the diet. When the liver can no longer produce cholesterol, levels of cholesterol in the blood will fall. Cholesterol synthesis appears to occur mostly at night, so statins with short half-lives are usually taken at night to maximize their effect. Studies have shown greater LDL and total cholesterol reductions in the short-acting simvastatin taken at night rather than the morning, but have shown no difference in the long-acting atorvastatin.
Increasing LDL uptake
In rabbits, hepatocytes (liver cells) sense the reduced levels of liver cholesterol and seek to compensate by synthesizing LDL receptors to draw cholesterol out of the circulation. This is accomplished via protease enzymes that cleave a protein called "membrane-bound sterol regulatory element binding protein", which migrates to the nucleus and causes increased production of various other proteins and enzymes, including the LDL receptor. The LDL receptor then relocates to the liver cell membrane and binds to passing LDL and VLDL particles (the "bad cholesterol" linked to disease). LDL and VLDL are drawn out of circulation into the liver, where the cholesterol is reprocessed into bile salts. These are excreted, and subsequently recycled mostly by an internal bile salt circulation.
Decreasing of specific protein prenylation
Statins, by inhibiting the HMG CoA reductase pathway, simultaneously inhibit the production of both cholesterol and specific prenylated proteins (see diagram). A 2012 study found that statin treatment increases lifespan and improves cardiac health in Drosophila by decreasing specific protein prenylation. The study concluded, "These data are the most direct evidence to date that decreased protein prenylation can increase cardiac health and lifespan in any metazoan [animal] species, and may explain the pleiotropic (non-cholesterol related) health effects of statins." This inhibitory effect on protein prenylation may be involved, at least partially, in the improvement of endothelial function and other pleiotropic cardiovascular benefits of statins, and may also account for certain of the benefits seen in cancer reduction with statins.
Statins exhibit action beyond lipid-lowering activity in the prevention of atherosclerosis. The ASTEROID trial showed direct ultrasound evidence of atheroma regression during statin therapy. Researchers hypothesize that statins prevent cardiovascular disease via four proposed mechanisms (all subjects of a large body of biomedical research):
- Improve endothelial function
- Modulate inflammatory responses
- Maintain plaque stability
- Prevent thrombus formation
There is controversy that statins may benefit those without high cholesterol. In 2008, the JUPITER study showed benefit in those who had no history of high cholesterol or heart disease, but only elevated C-reactive protein levels. An independent review did not consider the results of the trial to support these conclusions and raised concern of bias due to funding from the manufacturer.
Click on genes, proteins and metabolites below to link to respective articles. [§ 1]
- The interactive pathway map can be edited at WikiPathways: "Statin_Pathway_WP430".
A 2004 study showed patients with one of two common single-nucleotide polymorphisms (SNPs) (small genetic variations) in the HMG-CoA reductase gene were less responsive to statins. A 2008 study showed carriers of the KIF6 genetic mutation were more responsive to statin treatment.
Myopathy Adverse Drug Event
Likewise, a 2008 study demonstrated a link between an increased risk of myopathy at higher doses of statins (40–80 mg) and a SNP in SLCO1B1, a gene encoding for the organic anion transporter peptide OATP1B1. Genotyping or genome sequencing can be used to investigate preemptively to avoid myopathy in patients with increased risk. This risk is determined by the single nucleotide polymorphism rs4149056, also known as 37041T>C or V174A. The rs4149056(C) SNP defines the SLCO1B1*5 allele of the SLCO1B1 gene.
In 1971, Akira Endo, a Japanese biochemist working for the pharmaceutical company Sankyo, began the search for a cholesterol-lowering drug. Research had already shown cholesterol is mostly manufactured by the body in the liver, using the enzyme HMG-CoA reductase. Endo and his team reasoned that certain microorganisms may produce inhibitors of the enzyme to defend themselves against other organisms, as mevalonate is a precursor of many substances required by organisms for the maintenance of their cell walls (ergosterol) or cytoskeleton (isoprenoids). The first agent they identified was mevastatin (ML-236B), a molecule produced by the fungus Penicillium citrinum.
A British group isolated the same compound from Penicillium brevicompactum, named it compactin, and published their report in 1976. The British group mentions antifungal properties, with no mention of HMG-CoA reductase inhibition.
Mevastatin was never marketed, because of its adverse effects of tumors, muscle deterioration, and sometimes death in laboratory dogs. P. Roy Vagelos, chief scientist and later CEO of Merck & Co, was interested, and made several trips to Japan starting in 1975. By 1978, Merck had isolated lovastatin (mevinolin, MK803) from the fungus Aspergillus terreus, first marketed in 1987 as Mevacor.
A link between cholesterol and cardiovascular disease, known as the lipid hypothesis, had already been suggested. Cholesterol is the main constituent of atheroma, the fatty lumps in the wall of arteries that occur in atherosclerosis and, when ruptured, cause the vast majority of heart attacks. Treatment consisted mainly of dietary measures, such as a low-fat diet, and poorly tolerated medicines, such as clofibrate, cholestyramine, and nicotinic acid. Cholesterol researcher Daniel Steinberg writes that while the Coronary Primary Prevention Trial of 1984 demonstrated cholesterol lowering could significantly reduce the risk of heart attacks and angina, physicians, including cardiologists, remained largely unconvinced.
To market statins effectively, Merck had to convince the public about the dangers of high cholesterol, and doctors that statins were safe and would extend lives. As a result of public campaigns, people became familiar with their cholesterol numbers and the difference between "good" and "bad" cholesterol, and rival pharmaceutical companies began producing their own statins, such as pravastatin (Pravachol), manufactured by Sankyo and Bristol-Myers Squibb. In April 1994, the results of a Merck-sponsored study, the Scandinavian Simvastatin Survival Study, were announced. Researchers tested simvastatin, later sold by Merck as Zocor, on 4,444 patients with high cholesterol and heart disease. After five years, the study concluded the patients saw a 35% reduction in their cholesterol, and their chances of dying of a heart attack were reduced by 42%. In 1995, Zocor and Mevacor both made Merck over US$1 billion. Endo was awarded the 2006 Japan Prize, and the Lasker-DeBakey Clinical Medical Research Award in 2008.
|Cerivastatin||Lipobay, Baycol. (Withdrawn from the market in August, 2001 due to risk of serious Rhabdomyolysis)||Synthetic||various CYP3A isoforms |
|Fluvastatin||Lescol, Lescol XL||Synthetic||CYP2C9|
|Lovastatin||Mevacor, Altocor, Altoprev||Fermentation-derived. Naturally occurring compound. Found in oyster mushrooms and red yeast rice.||CYP3A4|
|Mevastatin||Compactin||Naturally occurring compound. Found in red yeast rice.||CYP3A4|
|Pravastatin||Pravachol, Selektine, Lipostat||Fermentation-derived. (A fermentation product of bacterium Nocardia autotrophica).||Non CYP|
|Rosuvastatin||Crestor||Synthetic||CYP2C9 and CYP2C19|
|Simvastatin||Zocor, Lipex||Fermentation-derived. (Simvastatin is a synthetic derivate of a fermentation product ofAspergillus terreus.)||CYP3A4|
|Lovastatin+Niacin extended-release||Advicor||Combination therapy|
|Atorvastatin+Amlodipine Besylate||Caduet||Combination therapy – Cholesterol+Blood Pressure|
|Simvastatin+Niacin extended-release||Simcor||Combination therapy|
LDL-lowering potency varies between agents. Cerivastatin is the most potent, (withdrawn from the market in August, 2001 due to risk of serious rhabdomyolysis) followed by (in order of decreasing potency), rosuvastatin, atorvastatin, simvastatin, lovastatin, pravastatin, and fluvastatin. The relative potency of pitavastatin has not yet been fully established.
Some types of statins are naturally occurring, and can be found in such foods as oyster mushrooms and red yeast rice. Randomized controlled trials found them to be effective, but the quality of the trials was low. Most of the block-buster branded statins will be generic by 2012, including atorvastatin, the largest-selling branded drug.
|Statin equivalent dosages|
|% LDL reduction (approx.)||Atorvastatin||Fluvastatin||Lovastatin||Pravastatin||Rosuvastatin||Simvastatin|
|10–20%||–||20 mg||10 mg||10 mg||–||5 mg|
|20–30%||–||40 mg||20 mg||20 mg||–||10 mg|
|30–40%||10 mg||80 mg||40 mg||40 mg||5 mg||20 mg|
|40–45%||20 mg||–||80 mg||80 mg||5–10 mg||40 mg|
|46–50%||40 mg||–||–||–||10–20 mg||80 mg*|
|50–55%||80 mg||–||–||–||20 mg||–|
|* 80-mg dose no longer recommended due to increased risk of rhabdomyolysis|
|Starting dose||10–20 mg||20 mg||10–20 mg||40 mg||10 mg; 5 mg if hypothyroid, >65 yo, Asian||20 mg|
|If higher LDL reduction goal||40 mg if >45%||40 mg if >25%||20 mg if >20%||--||20 mg if LDL >190 mg/dL (4.87 mmol/L)||40 mg if >45%|
|Optimal timing||Anytime||Evening||With evening meals||Anytime||Anytime||Evening|
Research continues into other areas where specific statins also appear to have a favorable effect, including dementia, lung cancer, nuclear cataracts, hypertension, and prostate cancer.
- Lewington S, Whitlock G, Clarke R et al. (December 2007). "Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths". Lancet 370 (9602): 1829–39. doi:10.1016/S0140-6736(07)61778-4. PMID 18061058.
- National Institute for Health and Clinical Excellence (May 2008, reissued March 2010). "Lipid modification – Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease – Quick reference guide" (PDF). Retrieved 2010-08-25.
- Taylor F, Huffman MD, Macedo AF, et al. (31 Jan 2013). "Statins for the primary prevention of cardiovascular disease". Cochrane Database of Systematic Reviews (1): CD004816. doi:10.1002/14651858.CD004816.pub5.
- Taylor F, Ward K, Moore TH et al. (2011). "Statins for the primary prevention of cardiovascular disease". In Taylor, Fiona. Cochrane Database Syst Rev (1): CD004816. doi:10.1002/14651858.CD004816.pub4. PMID 21249663.
- Naci, H.; Brugts, J.; Ades, T. (Jul 2013). "Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246 955 participants from 135 randomized, controlled trials.". Circ Cardiovasc Qual Outcomes 6 (4): 390–9. doi:10.1161/CIRCOUTCOMES.111.000071. PMID 23838105.
- Abd, TT; Jacobson, TA (2011 May). "Statin-induced myopathy: a review and update.". Expert opinion on drug safety 10 (3): 373–87. PMID 21342078.
- Sweetman, Sean C., ed. (2009). "Cardiovascular drugs". Martindale: the complete drug reference (36th ed.). London: Pharmaceutical Press. pp. 1155–434. ISBN 978-0-85369-840-1.
- Simons, John. "The $10 billion pill", Fortune magazine, January 20, 2003.
- "Doing Things Differently", Pfizer 2008 Annual Review, April 23, 2009, p. 15.
- National Cholesterol Education Program (2001). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Executive Summary. Bethesda, MD: National Institutes of Health. National Heart, Lung, and Blood Institute. p. 40. NIH Publication No. 01-3670.
- National Collaborating Centre for Primary Care (2010). NICE clinical guideline 67: Lipid modification (PDF). London: National Institute for Health and Clinical Excellence. p. 38.
- Ray et al. (2010). "Statins and All-Cause Mortality in High-Risk Primary Prevention: A Meta-analysis of 11 Randomized Controlled Trials Involving 65 229 Participants". Arch Intern Med 170 (12): 1024–31. doi:10.1001/archinternmed.2010.182. PMID 20585067. Retrieved 2010-11-04.
- Mills, EJ; Wu, P, Chong, G, Ghement, I, Singh, S, Akl, EA, Eyawo, O, Guyatt, G, Berwanger, O, Briel, M (February 2011). "Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials". QJM : monthly journal of the Association of Physicians 104 (2): 109–24. doi:10.1093/qjmed/hcq165. PMID 20934984.
- Tonelli, M; Lloyd, A, Clement, F, Conly, J, Husereau, D, Hemmelgarn, B, Klarenbach, S, McAlister, FA, Wiebe, N, Manns, B, for the Alberta Kidney Disease, Network (Nov 8, 2011). "Efficacy of statins for primary prevention in people at low cardiovascular risk: a meta-analysis". CMAJ : Canadian Medical Association 183 (16): E1189–E1202. doi:10.1503/cmaj.101280. PMC 3216447. PMID 21989464.
- Lebenthal Y, Horvath A, Dziechciarz P, Szajewska H, Shamir R (2010). "Are treatment targets for hypercholesterolemia evidence based? Systematic review and meta-analysis of randomised controlled trials". Arch Dis Child 95 (9): 673–80. doi:10.1136/adc.2008.157024. PMID 20515970.
- Law MR, Wald NJ, Rudnicka AR (June 2003). "Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis". BMJ 326 (7404): 1423. doi:10.1136/bmj.326.7404.1423. PMC 162260. PMID 12829554.
- Zhou Z, Rahme E, Pilote L (2006). "Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention". Am. Heart J. 151 (2): 273–81. doi:10.1016/j.ahj.2005.04.003. PMID 16442888.
- Abramson J, Wright J (2007). "Are lipid-lowering guidelines evidence-based?". Lancet 369 (9557): 168–9. doi:10.1016/S0140-6736(07)60084-1. PMID 17240267.
- Ravnskov U, Rosch P, Sutter M, Houston M (2006). "Should we lower cholesterol as much as possible?". BMJ 332 (7553): 1330–2. doi:10.1136/bmj.332.7553.1330. PMC 1473073. PMID 16740566.
- Grimes, D. (2006). "Are statins analogues of vitamin D?". The Lancet 368 (9529): 83–82. doi:10.1016/S0140-6736(06)68971-X.
- table adapted from the following source, but check individual references for technical explanations
- Consumer Reports; Drug Effectiveness Review Project (March 2013), "Evaluating statin drugs to treat High Cholesterol and Heart Disease: Comparing Effectiveness, Safety, and Price", Best Buy Drugs (Consumer Reports): 9, retrieved 27 March 2013
- Asberg, A. (2003). "Interactions between cyclosporin and lipid-lowering drugs: Implications for organ transplant recipients". Drugs 63 (4): 367–378. doi:10.2165/00003495-200363040-00003. PMID 12558459.
- Food and Drug Administration (1 March 2012). "Drug Safety and Availability; FDA Drug Safety Communication: Interactions between certain HIV or hepatitis C drugs and cholesterol-lowering statin drugs can increase the risk of muscle injury". fda.gov. Retrieved 3 April 2013.
- Bellosta, S. (2004). "Safety of Statins: Focus on Clinical Pharmacokinetics and Drug Interactions". Circulation 109 (23_suppl_1): III–I50. doi:10.1161/01.CIR.0000131519.15067.1f.
- Omar, M. A.; Wilson, J. P. (2002). "FDA Adverse Event Reports on Statin-Associated Rhabdomyolysis". The Annals of Pharmacotherapy 36 (2): 288–295. doi:10.1345/aph.1A289. PMID 11847951.
- Armitage, J. (2007). "The safety of statins in clinical practice". The Lancet 370 (9601): 1781–1790. doi:10.1016/S0140-6736(07)60716-8. PMID 17559928.
- Golomb BA, Evans MA (2008). "Statin Adverse Effects: A Review of the Literature and Evidence for a Mitochondrial Mechanism". Am J Cardiovasc Drugs 8 (6): 373–418. doi:10.2165/0129784-200808060-00004. PMC 2849981. PMID 19159124.
- Silva MA, Swanson AC, Gandhi PJ, Tataronis GR (January 2006). "Statin-related adverse events: a meta-analysis". Clin Ther 28 (1): 26–35. doi:10.1016/j.clinthera.2006.01.005. PMID 16490577.
- Finegold, JA; Manisty, CH; Goldacre, B; Barron, AJ; Francis, DP (2014 Mar 12). "What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice.". European journal of preventive cardiology. PMID 24623264.
- Anne Harding (August 28, 2007). "Docs often write off patient side effect concerns". Reuters. Retrieved 2009-10-06.
- Holman JR. (2007). Some Docs in Denial About Statin Side Effects. Doc News.
- Gaist D, Jeppesen U, Andersen M, García Rodríguez LA, Hallas J, Sindrup SH (2002). "Statins and risk of polyneuropathy – a case-control study". Neurology 58 (9): 1333–1337. doi:10.1212/WNL.58.9.1333. PMID 12011277. Lay summary – USA Today (2002-08-20).
- Sandra G. Boodman (September 10, 2002). "Study links statins to nerve damage". Pittsburgh Post-Gazette. The Washington Post. Retrieved 2009-10-06.
- Julie Appleby; Steve Sternberg (2002-08-18). "Statin side effect rare, but be aware". USA Today. Retrieved 2009-10-06.
- Ghirlanda G, Oradei A, Manto A, Lippa S, Uccioli L, Caputo S, Greco A, Littarru G (1993). "Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study". J Clin Pharmacol 33 (3): 226–9. doi:10.1002/j.1552-4604.1993.tb03948.x. PMID 8463436.
- Marcoff L, Thompson PD (2007). "The role of coenzyme Q10 in statin-associated myopathy: a systematic review". J. Am. Coll. Cardiol. 49 (23): 2231–7. doi:10.1016/j.jacc.2007.02.049. PMID 17560286.
- The SEARCH Collaborative Group (2008). "SLCO1B1 Variants and Statin-Induced Myopathy – A Genomewide Study". NEJM 359 (8): 789–799. doi:10.1056/NEJMoa0801936. PMID 18650507.
- Graham DJ, Staffa JA, Shatin D et al. (2004). "Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs". JAMA 292 (21): 2585–90. doi:10.1001/jama.292.21.2585. PMID 15572716.
- Hanai J, Cao P, Tanksale P et al. (2007). "The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity". J. Clin. Invest. 117 (12): 3940–51. doi:10.1172/JCI32741. PMC 2066198. PMID 17992259.
- Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ et al. (2010). "Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials". Lancet 375 (9716): 735–42. doi:10.1016/S0140-6736(09)61965-6. PMID 20167359.
- Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD et al. (2011). "Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis". JAMA 305 (24): 2556–64. doi:10.1001/jama.2011.860. PMID 21693744.
- Jukema, JW; Cannon, CP; de Craen, AJ; Westendorp, RG; Trompet, S (Sep 4, 2012). "The controversies of statin therapy: weighing the evidence.". Journal of the American College of Cardiology 60 (10): 875–81. PMID 22902202.
- Rutishauser, J (Nov 21, 2011). "Statins in clinical medicine.". Swiss medical weekly 141: w13310. PMID 22101921.
- Alsheikh-Ali AA; Maddukuri, PV; Han, H; Karas, RH (2007). "Effect of the Magnitude of Lipid Lowering on Risk of Elevated Liver Enzymes, Rhabdomyolysis, and Cancer: Insights from Large Randomized Statin Trials". Journal of the American College of Cardiology 50 (5): 409–418. doi:10.1016/j.jacc.2007.02.073. PMID 17662392.
- Dale KM, Coleman CI, Henyan NN, Kluger J, White CM (2006). "Statins and cancer risk: a meta-analysis". JAMA 295 (1): 74–80. doi:10.1001/jama.295.1.74. PMID 16391219.
- Alsheikh-Ali, AA; Karas, RH (March 2009). "The relationship of statins to rhabdomyolysis, malignancy, and hepatic toxicity: evidence from clinical trials.". Current atherosclerosis reports 11 (2): 100–4. PMID 19228482.
- Singh, S; Singh, AG; Singh, PP; Murad, MH; Iyer, PG (June 2013). "Statins are associated with reduced risk of esophageal cancer, particularly in patients with Barrett's esophagus: a systematic review and meta-analysis.". Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 11 (6): 620–9. PMID 23357487.
- Liu, Y; Tang, W; Wang, J; Xie, L; Li, T; He, Y; Deng, Y; Peng, Q; Li, S; Qin, X (Nov 22, 2013). "Association between statin use and colorectal cancer risk: a meta-analysis of 42 studies.". Cancer causes & control : CCC. PMID 24265089.
- Wu, XD; Zeng, K; Xue, FQ; Chen, JH; Chen, YQ (October 2013). "Statins are associated with reduced risk of gastric cancer: a meta-analysis.". European journal of clinical pharmacology 69 (10): 1855–60. PMID 23748751.
- Singh, PP; Singh, S (July 2013). "Statins are associated with reduced risk of gastric cancer: a systematic review and meta-analysis.". Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 24 (7): 1721–30. PMID 23599253.
- Pradelli, D; Soranna, D; Scotti, L; Zambon, A; Catapano, A; Mancia, G; La Vecchia, C; Corrao, G (May 2013). "Statins and primary liver cancer: a meta-analysis of observational studies.". European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) 22 (3): 229–34. PMID 23010949.
- Zhang, Y; Zang, T (2013). "Association between statin usage and prostate cancer prevention: a refined meta-analysis based on literature from the years 2005–2010.". Urologia internationalis 90 (3): 259–62. PMID 23052323.
- Bansal, D; Undela, K; D'Cruz, S; Schifano, F (2012). "Statin use and risk of prostate cancer: a meta-analysis of observational studies.". PloS one 7 (10): e46691. PMID 23049713.
- Tan, M; Song, X; Zhang, G; Peng, A; Li, X; Li, M; Liu, Y; Wang, C (2013). "Statins and the risk of lung cancer: a meta-analysis.". PloS one 8 (2): e57349. PMID 23468972.
- Zhang, XL; Liu, M; Qian, J; Zheng, JH; Zhang, XP; Guo, CC; Geng, J; Peng, B; Che, JP; Wu, Y (Jul 23, 2013). "Statin use and risk of kidney cancer: a meta-analysis of observational studies and randomized trials.". British journal of clinical pharmacology. PMID 23879311.
- Undela, K; Srikanth, V; Bansal, D (August 2012). "Statin use and risk of breast cancer: a meta-analysis of observational studies.". Breast cancer research and treatment 135 (1): 261–9. PMID 22806241.
- Cui, X; Xie, Y; Chen, M; Li, J; Liao, X; Shen, J; Shi, M; Li, W; Zheng, H; Jiang, B (July 2012). "Statin use and risk of pancreatic cancer: a meta-analysis.". Cancer causes & control : CCC 23 (7): 1099–111. PMID 22562222.
- Zhang, XL; Geng, J; Zhang, XP; Peng, B; Che, JP; Yan, Y; Wang, GC; Xia, SQ; Wu, Y; Zheng, JH (April 2013). "Statin use and risk of bladder cancer: a meta-analysis.". Cancer causes & control : CCC 24 (4): 769–76. PMID 23361339.
- Mayo clinic: article on interference between grapefruit and medication
- Kane GC, Lipsky JJ (2000). "Drug-grapefruit juice interactions". Mayo Clin. Proc. 75 (9): 933–42. doi:10.4065/75.9.933. PMID 10994829.
- Reamy, Brian V.; Stephens, Mark B. (July 15, 2007). "Letters to the Editor: The Grapefruit-Drug Interaction Debate: Role of Statins". American Family Physician 76 (2): 190–192.
- FDA Website Statins and HIV or Hepatitis C Drugs: Drug Safety Communication – Interaction Increases Risk of Muscle Injury
- Istvan, E. S.; Deisenhofer, J. (2001). "Structural Mechanism for Statin Inhibition of HMG-CoA Reductase". Science 292 (5519): 1160–1164. doi:10.1126/science.1059344. PMID 11349148.
- Endo A (1 November 1992). "The discovery and development of HMG-CoA reductase inhibitors" (PDF). J. Lipid Res. 33 (11): 1569–82. PMID 1464741.
- Miettinen TA (March 1982). "Diurnal variation of cholesterol precursors squalene and methyl sterols in human plasma lipoproteins". Journal of Lipid Research 23 (3): 466–73. PMID 7200504.
- Saito Y; Yoshida S; Nakaya N; Hata Y; Goto Y (Jul–Aug 1991). "Comparison between morning and evening doses of simvastatin in hyperlipidemic subjects. A double-blind comparative study". Arterioscler Thromb 11 (4): 816–26. doi:10.1161/01.ATV.11.4.816. PMID 2065035.
- Wallace A; Chinn D; Rubin G (4 October 2003). "Taking simvastatin in the morning compared with in the evening: randomised controlled trial". British Medical Journal 327 (7418): 788. doi:10.1136/bmj.327.7418.788. PMC 214096. PMID 14525878.
- Cilla DD Jr; Gibson DM; Whitfield LR; Sedman AJ (July 1996). "Pharmacodynamic effects and pharmacokinetics of atorvastatin after administration to normocholesterolemic subjects in the morning and evening". Journal of Clinical Pharmacology 36 (7): 604–9. PMID 8844442.
- Ma PT, Gil G, Südhof TC, Bilheimer DW, Goldstein JL, Brown MS (1986). "Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptor in livers of hamsters and rabbits" (PDF). Proc. Natl. Acad. Sci. U.S.A. 83 (21): 8370–4. Bibcode:1986PNAS...83.8370M. doi:10.1073/pnas.83.21.8370. PMC 386930. PMID 3464957.
- Spindler SR, Li R, Dhahbi JM, Yamakawa A, Mote P, Bodmer R, Ocorr K, Williams RT, Wang Y, Ablao KP (June 2012). "Statin treatment increases lifespan and improves cardiac health in Drosophila by decreasing specific protein prenylation". PLoS One 7 (6): e39581. doi:10.1371/journal.pone.0039581. PMID 22737247.
- Lahera V, Goicoechea M, de Vinuesa SG, Miana M, de las Heras N, Cachofeiro V, Luño J (2 2007). "Endothelial dysfunction, oxidative stress and inflammation in atherosclerosis: beneficial effects of statins". Curr Med Chem 14 (2): 243–8. doi:10.2174/092986707779313381. PMID 17266583.
- Ferri N, Colombo G, Ferrandi C, Raines EW, Levkau B, Corsini A (May 2007). "Simvastatin reduces MMP1 expression in human smooth muscle cells cultured on polymerized collagen by inhibiting Rac1 activation". Arterioscler Thromb Vasc Biol 27 (5): 1043–9. doi:10.1161/ATVBAHA.107.139881. PMID 17303772.
- Thurnher M, Nussbaumer O, Gruenbacher G (Jul 2012). "Novel aspects of mevalonate pathway inhibitors as antitumor agents". Clin Cancer Res 18 (13): 3524–31. doi:10.1158/1078-0432.CCR-12-0489. PMID 22529099.
- Nissen S, Nicholls S, Sipahi I, Libby P, Raichlen J, Ballantyne C, Davignon J, Erbel R, Fruchart J, Tardif J, Schoenhagen P, Crowe T, Cain V, Wolski K, Goormastic M, Tuzcu E (2006). "Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial". JAMA 295 (13): 1556–65. doi:10.1001/jama.295.13.jpc60002. PMID 16533939.
- Furberg CD (19 January 1999). "Natural Statins and Stroke Risk". Circulation 99 (2): 185–188. doi:10.1161/01.CIR.99.2.185. PMID 9892578.
- Ridker PM, Danielson E, Fonseca FAH et al. (2008). "Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein". NEJM 359 (21): 2195–207. doi:10.1056/NEJMoa0807646. PMID 18997196.
- de Lorgeril, M; Salen, P; Abramson, J; Dodin, S; Hamazaki, T; Kostucki, W; Okuyama, H; Pavy, B; Rabaeus, M (Jun 28, 2010). "Cholesterol lowering, cardiovascular diseases, and the rosuvastatin-JUPITER controversy: a critical reappraisal.". Archives of internal medicine 170 (12): 1032–6. PMID 20585068.
- Chasman DI, Posada D, Subrahmanyan L, Cook NR, Stanton VP, Ridker PM (2004). "Pharmacogenetic study of statin therapy and cholesterol reduction". JAMA 291 (23): 2821–7. doi:10.1001/jama.291.23.2821. PMID 15199031.
- Iakoubova, O. A.; Sabatine, M. S.; Rowland, C. M.; Tong, C. H.; Catanese, J. J.; Ranade, K.; Simonsen, K. L.; Kirchgessner, T. G.; Cannon, C. P.; Devlin, J. J.; Braunwald, E. (2008). "Polymorphism in KIF6 Gene and Benefit from Statins After Acute Coronary Syndromes: Results from the PROVE IT-TIMI 22 Study". Journal of the American College of Cardiology 51 (4): 449–55. doi:10.1016/j.jacc.2007.10.017. PMID 18222355.
- Huser, V.; Cimino, J. J. (2013). "Providing pharmacogenomics clinical decision support using whole genome sequencing data as input". AMIA Summits on Translational Science proceedings AMIA Summit on Translational Science 2013: 81. PMC 3814493. PMID 24303303.
- "Crystal and Molecular Structure of Compactin, a New Antifungal Metabolite from Penicillium brevicompactum." Alian G. Brown, Terry C. Smale, Trevor J. King, Rainer Hasenkamp and Ronald H. Thompson. J. Chem. Soc., Perkin Trans. 1, 1976, 1165–1170. doi:10.1039/P19760001165
- Steinberg, Daniel. The Cholesterol Wars: The Skeptics vs. The Preponderance of Evidence. Academic Press, 2007, pp. 6–9.
- Scandinaviansimvastatinsurvival (November 1994). "Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)". Lancet 344 (8934): 1383–9. doi:10.1016/S0140-6736(94)90566-5. PMID 7968073.
- Safety of Statins: Focus on Clinical Pharmacokinetics and Drug Interactions" Circulation 2004:109:III-50-IIIi-57
- "Metabolism of cerivastatin by human liver microsomes in vitro. Characterization of primary metabolic pathways and of cytochrome P450 isozymes involved". Drug Metab Dispos 25 (3): 321–31. Mar 1997.
- Comparison of Cytochrome P-450-Dependent Metabolism and Drug Interactions of the 3-Hydroxy-3-methylglutaryl-CoA Reductase Inhibitors Lovastatin and Pravastatin in the Liver. DMD February 1, 1999 vol. 27 no. 2 173–179
- Shepherd J, Hunninghake DB, Barter P, McKenney JM, Hutchinson HG (2003). "Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals". Am. J. Cardiol. 91 (5A): 11C–17C; discussion 17C–19C. doi:10.1016/S0002-9149(03)00004-3. PMID 12646338.
- Liu J, Zhang J, Shi Y, Grimsgaard S, Alraek T, Fønnebø V (2006). "Chinese red yeast rice (Monascus purpureus) for primary hyperlipidemia: a meta-analysis of randomized controlled trials". Chin Med 1: 4. doi:10.1186/1749-8546-1-4. PMC 1761143. PMID 17302963.
- Wolozin, B; Wang SW, Li NC, Lee A, Lee TA, Kazis LE (July 19, 2007). "Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease". BMC Medicine 5: 20. doi:10.1186/1741-7015-5-20. PMC 1955446. PMID 17640385.
- Khurana V, Bejjanki HR, Caldito G, Owens MW (May 2007). "Statins reduce the risk of lung cancer in humans: a large case-control study of US veterans". Chest 131 (5): 1282–1288. doi:10.1378/chest.06-0931. PMID 17494779.
- Klein BE, Klein R, Lee KE, Grady LM (June 2006). "Statin use and incident nuclear cataract". JAMA 295 (23): 2752–8. doi:10.1001/jama.295.23.2752. PMID 16788130.
- Golomb BA, Dimsdale JE, White HL, Ritchie JB, Criqui MH (April 2008). "Reduction in blood pressure with statins: results from the UCSD Statin Study, a randomized trial". Arch. Intern. Med. 168 (7): 721–7. doi:10.1001/archinte.168.7.721. PMID 18413554.
- Mondul AM, Han M, Humphreys EB, Meinhold CL, Walsh PC, Platz EA (February 2011). "Association of statin use with pathological tumor characteristics and prostate cancer recurrence after surgery". Journal of Urology 185 (4): 1268–1273. doi:10.1016/j.juro.2010.11.089. PMID 21334020.